Pharmacy(BK4007),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4007 Pharmacy

Trading 12-11 09:43:53 EST

832.43

+2.76

+0.33%

High837.95	Low829.62	Vol40.67M
Open829.67	D1 Closing829.67	Amplitude1.00%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O1.40B	T/O Rate--	Tradable Shares0.00
P/B4.990116	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4007","market":"US","secType":"PLATE","nameCN":"Pharmacy","latestPrice":832.43066,"timestamp":1765464232858,"preClose":829.669,"halted":0,"volume":40665979,"delay":0,"changeRate":0.003329,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":2.761658,"latestTime":"12-11 09:43:53 EST","open":829.669,"high":837.94794,"low":829.6186,"amount":1401316463.312485,"amplitude":0.010039,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.990116,"peRate":24.17914,"turnoverRate":0.000891,"increases":106,"decrements":75,"flats":9,"marketCap":3302811595064.875,"floatMarketCap":3151027786372.25},"requestUrl":"/m/hq/s/BK4007/wiki","defaultTab":"wiki","newsList":[{"id":"1119562380","title":"Eli Lilly Reports Positive Clinical Trial Results for Next-Gen Weight Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1119562380","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119562380?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:22","pubTimestamp":1765462921,"startTime":"0","endTime":"0","summary":"Eli Lilly announced that its next-generation weight loss drug, retatrutide, demonstrated significant weight reduction and alleviated knee pain in participants during a late-stage clinical trial. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443895.HKD","LU0203201768.USD","LU0466842654.USD","LU1093756168.USD","SG9999014898.SGD","IE00BK4W5M84.HKD","SG9999017495.SGD","LU1061106388.HKD","LU1035775433.USD","BK4581","IE00BFSS7M15.SGD","LU2746668461.USD","LU1868836914.USD","LU0708995401.HKD","LU1804176565.USD","LU2461242641.AUD","IE00B7KXQ091.USD","LU0198837287.USD","LU2237443382.USD","LU2168563687.JPY","IE0004445239.USD","LU2236285917.USD","LU0820561909.HKD","IE00BWXC8680.SGD","LU1548497426.USD","BK4533","IE0004445015.USD","LU1232071149.USD","BK4588","LU1623119135.USD","LU2361045086.USD","LU0417517546.SGD","LU0109391861.USD","LU2471134523.USD","LU1093756325.SGD","LU0094547139.USD","SG9999014914.USD","SGXZ31699556.SGD","IE0002141913.USD","LU1720051017.SGD","LU1974910355.USD","LU1064131342.USD","LU2023250504.SGD","IE00BKDWB100.SGD","IE00B775H168.HKD","IE00BFTCPJ56.SGD","LU0006306889.USD","LU0238689110.USD","LU2237443622.USD","LU2750360641.GBP","LU2089984988.USD","IE00BJJMRY28.SGD","LU2491050071.SGD","LU2462157665.USD","IE00BKPKM429.USD","LU2168564495.EUR","LU1983299246.USD","IE00B2B36J28.USD","BK4534","LU1868836591.USD","BK4516","LU1868837136.USD","LU1291159041.SGD","LU0882574055.USD","LU2168564065.EUR","SG9999001176.USD","LU2456880835.USD","LU0320765059.SGD","LU0820561818.USD","LU1127390331.HKD","IE00BJJMRX11.SGD","LU2237443549.SGD","IE0005OL40V9.USD","LU2237438978.USD","LU2552382058.USD","LU1366192091.USD","LU0097036916.USD","IE00BN29S564.USD","LU2471134879.HKD","LU0234572021.USD","SG9999013999.USD","IE0009355771.USD","LU0266013472.USD","LU0122379950.USD","LU2211815571.USD","LU1023059063.AUD","LU1917777945.USD","LU0640476718.USD","LU1267930730.SGD","LU0354030511.USD","SG9999015978.USD","SG9999015986.USD","LU2106854487.HKD","LU2361044865.SGD","LU0471298694.HKD","LU2750360997.AUD","LU1814569148.SGD","LU2602419157.SGD","SG9999015952.SGD","LU1069344957.HKD","LU0353189680.USD","LU2471134952.CNY","LU1280957306.USD","SG9999018865.SGD","IE00BFSS8Q28.SGD","LU0689472784.USD","LU2265009873.SGD","SG9999018857.SGD","LU0256863811.USD","LU0058720904.USD","LU2357305700.SGD","BK4599","LU0106261372.USD","LU1057294990.SGD","SG9999001176.SGD","LU2417539215.USD","SG9999014906.USD","SGXZ57979304.SGD","LU0471298777.SGD","LU1551013342.USD","LU2552382215.SGD","LU0354030438.USD","LU2087625088.SGD","LU0114720955.EUR","LU0823416689.USD","BK4585","LU0385154629.USD","IE00B4JS1V06.HKD","LU0823434583.USD","SGXZ81514606.USD","LU2491049909.HKD","LU0456855351.SGD","SGXZ51526630.SGD","LU0882574139.USD","LU2168564149.EUR","GB00BDT5M118.USD","LU0320765992.SGD","LU0289739699.SGD","LU2264538146.SGD","IE00B1XK9C88.USD","IE00BJJMRZ35.SGD","LU1868837300.USD","LU0889565916.HKD","BK4007","LU0672654240.SGD","LU0323591593.USD","LU0203202063.USD","LU2108987350.USD","LU2360106947.USD","LU1988902786.USD","LU2063271972.USD","IE00BJT1NW94.SGD","LU0256863902.USD","LU2112291526.USD","LU0079474960.USD","LU1323610961.USD","LU1868836757.USD","LU0823434740.USD","LU2491050154.USD","LU1712237335.SGD","IE00BK4W5L77.USD","LU0353189763.USD","SG9999014880.SGD","LU2324357040.USD","LU0432979614.USD","LU2552382132.HKD","LU1551013425.SGD","LLY","LU2471134796.USD","IE00BJLML261.HKD","SGXZ99366536.SGD","IE00B4R5TH58.HKD","IE00B1BXHZ80.USD","LU0943347566.SGD","LU0316494557.USD","LU0786609619.USD","LU2168564222.USD","LU0061475181.USD","LU2468319806.SGD","LU1720051108.HKD","LU0109394709.USD","LU1989771016.USD","LU2237443465.HKD","LU0096364046.USD","LU2237443978.SGD","LU2361044949.HKD","LU2746668974.SGD","SG9999015945.SGD"],"gpt_icon":1},{"id":"2590511214","title":"Sector Update: Health Care Stocks Mixed Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511214","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511214?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:18","pubTimestamp":1765462684,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF  up 0.3% and the iShares Biotechnology ETF  0.2% lower.Rezolute  shares were down more than 88% after the company said its phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism did not meet its primary and key secondary endpoints.Sarepta Therapeutics  stock was down nearly 7% after the company said it has negotiated exchange agreements with a limited number of holders of its 1.25% convertible senior notes due 2027.IDEAYA Biosciences  shares were up nearly 3% after the company said it has completed its targeted full enrollment of 435 patients in the phase 2/3 trial evaluating darovasertib in combination with Pfizer's  crizotinib for the treatment of metastatic uveal melanoma, a form of ocular cancer.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4592","SG9999003800.SGD","LU0985481810.HKD","BK4581","BK7095","RZLT","BK4533","SG9999013999.USD","IE00B2B36J28.USD","LU0289739699.SGD","LU0321505439.SGD","LU0321505868.SGD","SG9999001176.SGD","BK4588","LU0225284248.USD","SG9999002224.SGD","SRPT","LU0456855351.SGD","LU1057294990.SGD","BK4599","IE00BLSP4239.USD","SG9999002232.USD","BK4007","IE0009355771.USD","IDYA","IE00B19Z3B42.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","SGXZ57979304.SGD","BK4550","LU0122379950.USD","LU1066051498.USD","BK4568","IE0002141913.USD","LABU","XBI","BK4585","IE00BLSP4452.SGD","LU0868494617.USD","IE00BBT3K403.USD","LU1894683348.USD","LU0170899867.USD","LU1023059063.AUD","LU1066053197.SGD","LU1894683264.USD","SG9999001176.USD","IE000M9KFDE8.USD","LU0225771236.USD","IE00BJJMRZ35.SGD","LU0234572021.USD","BK4139","IE0002270589.USD","LU0306807586.USD","SG9999011175.SGD","BK4534","LU0306806265.USD","LU0058720904.USD","LU1883839398.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2590111065","title":"GRI Bio Announces Pricing of $8,000,000 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590111065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590111065?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:15","pubTimestamp":1765462500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA5ZGKSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRI","BK4139","BK4007"],"gpt_icon":0},{"id":"2590511175","title":"Roivant Sciences Fast-Tracks Key Drug Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511175","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511175?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:11","pubTimestamp":1765462310,"startTime":"0","endTime":"0","summary":"Roivant Sciences  said Thursday it has fast-tracked four of its key drug development programs.The new drug application filing for Brepocitinib in dermatomyositis is now expected early next year, with a commercial launch expected in early 2027. The company said its phase 3 trial for the drug candidate in non-infectious uveitis is fully enrolled, with topline data now expected in H2 2026.Meanwhile, the Brepocitinib proof-of-concept trial in cutaneous sarcoidosis is fully enrolled, with topline data expected in H1 2026.For the IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis, topline data are now expected next year, the company said.Roivant also said it led a funding round for Immunovant  that garnered gross proceeds of around $550 million. The funding will extend Immunovant's cash runway to the launch of IMVT-1402 in Graves' disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IMVT","BK4139","BK4007","BK4585","ROIV"],"gpt_icon":0},{"id":"2590051139","title":"BRIEF-Enliven Therapeutics Announces New CEO To Drive Next Phase Of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2590051139","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590051139?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:02","pubTimestamp":1765461755,"startTime":"0","endTime":"0","summary":"BRIEF-Enliven Therapeutics Announces New CEO To Drive Next Phase Of DevelopmentDec 11 (Reuters) - Enliven Therapeutics Inc ELVN.O:ENLIVEN THERAPEUTICS ANNOUNCES NEW CEO TO DRIVE NEXT PHASE OF DEVELOPM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA71MF5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2590113555","title":"Enliven Therapeutics Names Rick Fair CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590113555","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590113555?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:01","pubTimestamp":1765461686,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has appointed Rick Fair as Chief Executive Officer and member of the Board of Directors, effective December 11, 2025. Co-founder and former CEO Sam Kintz will transition to the role of Head of Pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLbxthbl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2590828511","title":"Enliven Therapeutics Inc - Rick Fair Appointed CEO and Board Member Effective Dec 11, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590828511","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590828511?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:00","pubTimestamp":1765461606,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA71MF5K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2590511846","title":"Enliven Therapeutics Announces New CEO to Drive Next Phase of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511846","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511846?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:00","pubTimestamp":1765461606,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA71MF5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2590511844","title":"Enliven Therapeutics Inc - Rick Fair Joins Enliven as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590511844?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:00","pubTimestamp":1765461606,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA71MF5K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"1116190585","title":"Eli Lilly's \"Triple G\" Obesity Drug Shows Record 23.7% Weight Loss in Trials, Also Eases Knee Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=1116190585","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116190585?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:55","pubTimestamp":1765461355,"startTime":"0","endTime":"0","summary":"Could this be the most potent obesity treatment yet? Eli Lilly's experimental drug retatrutide has demonstrated unprecedented weight loss results in late-stage clinical trials while significantly...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B775H168.HKD","LU2023250504.SGD","SG9999015978.USD","IE00BJJMRY28.SGD","LU1064131342.USD","IE0004445239.USD","LU0432979614.USD","LU2237443978.SGD","GB00BDT5M118.USD","LU2462157665.USD","LU1623119135.USD","LU2265009873.SGD","LU2461242641.AUD","LU0466842654.USD","LU1127390331.HKD","LU1323610961.USD","IE00B1BXHZ80.USD","LU2491050154.USD","IE00B1XK9C88.USD","LU0672654240.SGD","LU0640476718.USD","IE00BJJMRZ35.SGD","LU1366192091.USD","IE00BK4W5M84.HKD","LU1868837136.USD","LU0353189680.USD","SG9999018857.SGD","LU0114720955.EUR","LU2552382132.HKD","LU2237443549.SGD","LU2237443622.USD","LU2552382215.SGD","BK4585","LU1093756168.USD","LU0266013472.USD","LU0316494557.USD","LU0786609619.USD","LU1280957306.USD","LU2361044949.HKD","LU0122379950.USD","LU0106261372.USD","IE00BFSS8Q28.SGD","LU2746668974.SGD","SGXZ31699556.SGD","IE00BWXC8680.SGD","LU0079474960.USD","LU1988902786.USD","IE00BKPKM429.USD","LU1267930730.SGD","LU1057294990.SGD","LU2602419157.SGD","LU1917777945.USD","SG9999015952.SGD","IE00BJJMRX11.SGD","LU2168564149.EUR","LU2168564065.EUR","IE0009355771.USD","LU0471298777.SGD","IE0005OL40V9.USD","IE00BK4W5L77.USD","LU0820561909.HKD","IE00BN29S564.USD","BK4599","LU0823434740.USD","LU0198837287.USD","LLY","IE0004445015.USD","LU0708995401.HKD","LU2471134879.HKD","LU0354030438.USD","LU0471298694.HKD","LU0323591593.USD","LU0203202063.USD","LU2089984988.USD","LU2237443465.HKD","LU1814569148.SGD","LU2471134796.USD","SG9999013999.USD","LU0353189763.USD","LU2750360641.GBP","LU1069344957.HKD","LU1551013425.SGD","LU1061106388.HKD","LU2361045086.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","IE00BFSS7M15.SGD","LU2211815571.USD","LU0354030511.USD","LU2237438978.USD","IE00B4R5TH58.HKD","SG9999014914.USD","LU2491049909.HKD","SGXZ51526630.SGD","LU1868836757.USD","LU2112291526.USD","BK4588","LU0823434583.USD","LU2063271972.USD","LU2361044865.SGD","SG9999001176.SGD","SG9999017495.SGD","LU2237443895.HKD","LU0094547139.USD","LU1712237335.SGD","LU0320765992.SGD","SG9999015986.USD","LU1720051017.SGD","SGXZ81514606.USD","BK4516","LU1868836914.USD","LU2491050071.SGD","IE00B7KXQ091.USD","LU2746668461.USD","LU1983299246.USD","LU1035775433.USD","LU0689472784.USD","IE0002141913.USD","LU0320765059.SGD","SGXZ99366536.SGD","SGXZ57979304.SGD","LU2456880835.USD","LU0097036916.USD","LU0234572021.USD","BK4581","IE00BJT1NW94.SGD","LU2087625088.SGD","IE00BJLML261.HKD","SG9999015945.SGD","LU0943347566.SGD","LU2552382058.USD","LU1232071149.USD","LU0096364046.USD","LU0256863811.USD","LU1720051108.HKD","LU2108987350.USD","LU0058720904.USD","LU0061475181.USD","LU2471134952.CNY","LU0385154629.USD","LU0006306889.USD","BK4534","SG9999014906.USD","LU2168564495.EUR","LU2106854487.HKD","LU0109391861.USD","LU2360106947.USD","SG9999014880.SGD","BK4533","LU2417539215.USD","LU0109394709.USD","LU0889565916.HKD","LU1804176565.USD","LU0882574055.USD","LU2236285917.USD","LU1551013342.USD","LU0820561818.USD","LU1093756325.SGD","LU0456855351.SGD","LU1868837300.USD","LU0882574139.USD","LU0203201768.USD","SG9999014898.SGD","LU1989771016.USD","SG9999001176.USD","LU2324357040.USD","LU2168564222.USD","LU0256863902.USD","LU0289739699.SGD","LU2471134523.USD","BK4007","LU0238689110.USD","LU2750360997.AUD","LU1974910355.USD","LU1548497426.USD","IE00BKDWB100.SGD","LU2168563687.JPY","LU2264538146.SGD","IE00B2B36J28.USD","LU2357305700.SGD","IE00B4JS1V06.HKD","LU0823416689.USD","LU2237443382.USD","LU1868836591.USD","LU0417517546.SGD","SG9999018865.SGD","LU1291159041.SGD","LU2468319806.SGD"],"gpt_icon":1},{"id":"2590196405","title":"Correction to Lilly Positive Study Results First Article","url":"https://stock-news.laohu8.com/highlight/detail?id=2590196405","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590196405?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:38","pubTimestamp":1765460280,"startTime":"0","endTime":"0","summary":"Kenneth Custer is the president of Lilly Cardiometabolic Health. \"Eli Lilly Reports Positive Results From Study of Weight Loss Drug for Patients with Osteoarthritis,\" at 7:08 a.m. ET, incorrectly spelled his name.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2471134952.CNY","SG9999014914.USD","LU1035775433.USD","BK4533","LU0640476718.USD","IE0004445015.USD","LU0122379950.USD","LU0266013472.USD","LU1988902786.USD","LU0820561909.HKD","IE00BJJMRX11.SGD","LU2552382215.SGD","IE00B1XK9C88.USD","IE00BJJMRZ35.SGD","LU0094547139.USD","LU2602419157.SGD","LU0353189763.USD","LU2168563687.JPY","LU2361044865.SGD","SG9999014898.SGD","LU0786609619.USD","LU2491050154.USD","LU0234572021.USD","LU1069344957.HKD","BK4516","IE00BN29S564.USD","LU0353189680.USD","LU2357305700.SGD","LU2552382132.HKD","LU2750360997.AUD","LU2168564495.EUR","LU0354030511.USD","LU1093756168.USD","SGXZ99366536.SGD","LU0316494557.USD","LU0823434583.USD","LU0198837287.USD","IE00BK4W5L77.USD","LU1989771016.USD","LU0106261372.USD","LU1974910355.USD","IE00B7KXQ091.USD","LU0466842654.USD","SG9999001176.SGD","LU0114720955.EUR","LU0432979614.USD","SG9999015945.SGD","LU2112291526.USD","IE0009355771.USD","SG9999013999.USD","LU2237443895.HKD","LU2471134523.USD","LU1720051108.HKD","SG9999001176.USD","LU2211815571.USD","LU0471298694.HKD","LU2264538146.SGD","LU0882574139.USD","LU2237443382.USD","IE00BJLML261.HKD","LU2750360641.GBP","IE00BWXC8680.SGD","LU0943347566.SGD","LU0385154629.USD","LU1064131342.USD","LU1127390331.HKD","LU1267930730.SGD","LU2237443465.HKD","SG9999015986.USD","LU1291159041.SGD","IE00BFSS7M15.SGD","LLY","LU1983299246.USD","IE0002141913.USD","SG9999017495.SGD","LU1623119135.USD","IE00BKDWB100.SGD","LU2237438978.USD","LU0203202063.USD","IE00BKPKM429.USD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","LU2471134796.USD","LU2746668974.SGD","LU2361044949.HKD","IE00B2B36J28.USD","LU2361045086.USD","LU0889565916.HKD","LU1917777945.USD","LU0354030438.USD","LU0203201768.USD","LU0820561818.USD","LU1093756325.SGD","LU1551013342.USD","LU1548497426.USD","LU2456880835.USD","LU0323591593.USD","LU2462157665.USD","LU0320765059.SGD","IE00B4JS1V06.HKD","LU0109394709.USD","IE0004445239.USD","LU0320765992.SGD","IE00B1BXHZ80.USD","IE00BFSS8Q28.SGD","LU2471134879.HKD","LU0096364046.USD","LU0823434740.USD","LU2360106947.USD","LU0079474960.USD","LU0708995401.HKD","IE00B4R5TH58.HKD","LU1232071149.USD","LU2023250504.SGD","LU2237443978.SGD","LU0238689110.USD","IE00BK4W5M84.HKD","IE0005OL40V9.USD","LU2417539215.USD","LU2324357040.USD","LU0689472784.USD","SG9999015952.SGD","LU2491050071.SGD","LU1814569148.SGD","LU1868837136.USD","LU1061106388.HKD","BK4588","LU0456855351.SGD","LU0882574055.USD","LU1551013425.SGD","BK4581","LU0823416689.USD","LU0471298777.SGD","LU1712237335.SGD","LU1868836591.USD","SG9999018857.SGD","SGXZ51526630.SGD","IE00B775H168.HKD","SG9999014880.SGD","LU0109391861.USD","LU2237443549.SGD","IE00BJT1NW94.SGD","LU0058720904.USD","SG9999018865.SGD","SGXZ81514606.USD","LU1868836757.USD","LU2063271972.USD","LU0256863902.USD","BK4585","LU1323610961.USD","LU2236285917.USD","LU1023059063.AUD","LU2168564065.EUR","LU2746668461.USD","LU1280957306.USD","LU1868836914.USD","LU0097036916.USD","LU2168564149.EUR","LU2237443622.USD","LU2168564222.USD","LU0256863811.USD","LU1366192091.USD","BK4534","LU1868837300.USD","LU0006306889.USD","LU1057294990.SGD","LU2552382058.USD","LU0289739699.SGD","LU0672654240.SGD","LU2491049909.HKD","LU2089984988.USD","GB00BDT5M118.USD","LU2087625088.SGD","LU1804176565.USD","LU0417517546.SGD","LU0061475181.USD","LU1720051017.SGD","LU2461242641.AUD","LU2108987350.USD","SG9999014906.USD","IE00BJJMRY28.SGD","BK4599","LU2265009873.SGD","LU2106854487.HKD","SGXZ31699556.SGD","SG9999015978.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"1175589281","title":"Danish Weight-Loss Drugmaker Zealand Unveils Ambitious 2030 Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1175589281","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175589281?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:33","pubTimestamp":1765460017,"startTime":"0","endTime":"0","summary":"Danish biopharmaceutical company Zealand Pharma A/S (ZEAL) announced an ambitious five-year strategy for its anti-obesity drug portfolio on Thursday, highlighting intensifying competition from...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","IE00BZ1G4Q59.USD","BK4007","BK4599","BK4588","BK1191","01477","BK4585","ZEAL","BK1574","NVO","LU1093756325.SGD","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD"],"gpt_icon":1},{"id":"2590383519","title":"Black Titan Corporation Unveils DAT+ Strategy to Evaluate Digital Assets Based on Utility, Risk Management, Earnings Alignment, Strategic Partnerships, and Liquidity Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=2590383519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590383519?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:30","pubTimestamp":1765459829,"startTime":"0","endTime":"0","summary":"Black Titan Corporation Unveils DAT+ Strategy to Evaluate Digital Assets Based on Utility, Risk Management, Earnings Alignment, Strategic Partnerships, and Liquidity Standards. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Titan Corporation published the original content used to generate this news brief via ACCESS Newswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL175Hvf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4182","BK4196","BTTC","BK4129","BK4134"],"gpt_icon":0},{"id":"1198258782","title":"Weight Loss Up to 23%! Eli Lilly's (LLY.US) New Obesity Drug Stuns Market: Patients Stop Due to Excessive Efficacy, Shares Rise Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=1198258782","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198258782?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:11","pubTimestamp":1765458718,"startTime":"0","endTime":"0","summary":"Eli Lilly's (LLY.US) next-generation obesity treatment injection has demonstrated unprecedented weight loss results in clinical trials, reducing patients' body weight by nearly a quarter—potentially...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2471134523.USD","LU0256863811.USD","LU0432979614.USD","LU2746668974.SGD","LU2237443895.HKD","LU2237443465.HKD","LU2265009873.SGD","LU0640476718.USD","LU1917777945.USD","LU2112291526.USD","LU0708995401.HKD","LU1057294990.SGD","LU0106261372.USD","LU0238689110.USD","LU0385154629.USD","LU2471134796.USD","LU1127390331.HKD","IE0002141913.USD","IE00BKPKM429.USD","LU0823416689.USD","LU1551013425.SGD","SG9999017495.SGD","LU0061475181.USD","LU1868837136.USD","LU1280957306.USD","BK4599","LU0114720955.EUR","LU2750360997.AUD","IE00B2B36J28.USD","SG9999013999.USD","LU1548497426.USD","LU0203201768.USD","IE00BJJMRZ35.SGD","LU1974910355.USD","LU0943347566.SGD","LU2552382132.HKD","LU1720051017.SGD","LU2108987350.USD","LU1069344957.HKD","LU1267930730.SGD","LU0456855351.SGD","IE0004445239.USD","BK4534","LU2746668461.USD","IE00B7KXQ091.USD","LU1868836757.USD","LU0820561909.HKD","LU2168564065.EUR","GB00BDT5M118.USD","LU2237443622.USD","IE00BKDWB100.SGD","LU2360106947.USD","LU1989771016.USD","LU0058720904.USD","LU0097036916.USD","LU2471134879.HKD","LU2236285917.USD","LU1023059063.AUD","IE00BFSS7M15.SGD","LU0353189763.USD","IE00BJJMRY28.SGD","LU0198837287.USD","LU2471134952.CNY","LU1868837300.USD","LU1623119135.USD","IE00BK4W5M84.HKD","LU0320765992.SGD","BK4585","LU1093756168.USD","LU1323610961.USD","LU2461242641.AUD","LU0786609619.USD","LU1366192091.USD","SG9999014914.USD","IE00BJT1NW94.SGD","LU0823434740.USD","LU0256863902.USD","LU2602419157.SGD","LU0320765059.SGD","BK4581","LU0323591593.USD","LU0109391861.USD","IE00B1BXHZ80.USD","LU0094547139.USD","LU1035775433.USD","SG9999001176.SGD","LU0882574055.USD","LU2552382215.SGD","IE0009355771.USD","LU2168563687.JPY","IE00B4R5TH58.HKD","LU2237438978.USD","SG9999014898.SGD","LU2361044949.HKD","LU2106854487.HKD","IE00BK4W5L77.USD","LU0823434583.USD","LU2168564495.EUR","LU1868836591.USD","LU0889565916.HKD","LU0471298777.SGD","LU0820561818.USD","IE00BFSS8Q28.SGD","LU2023250504.SGD","LU2417539215.USD","SGXZ57979304.SGD","IE00BWXC8680.SGD","LU1814569148.SGD","IE00BFTCPJ56.SGD","SG9999015978.USD","LU1868836914.USD","SG9999014906.USD","LU0109394709.USD","LU1232071149.USD","LU1712237335.SGD","IE00B4JS1V06.HKD","IE0004445015.USD","IE00B1XK9C88.USD","SG9999014880.SGD","LU2357305700.SGD","LU2264538146.SGD","LU2237443549.SGD","LU2089984988.USD","LU1064131342.USD","SGXZ81514606.USD","LU2491050071.SGD","SG9999015952.SGD","LU2491050154.USD","BK4007","SGXZ51526630.SGD","LU0466842654.USD","SG9999001176.USD","LU2361045086.USD","BK4533","SG9999015986.USD","SGXZ31699556.SGD","LLY","LU2462157665.USD","BK4516","LU1720051108.HKD","LU1093756325.SGD","IE00BJLML261.HKD","IE00BJJMRX11.SGD","LU2087625088.SGD","LU0316494557.USD","LU0417517546.SGD","LU0266013472.USD","LU2168564149.EUR","LU2456880835.USD","LU0203202063.USD","BK4588","LU1988902786.USD","IE0005OL40V9.USD","LU1551013342.USD","LU0882574139.USD","LU2237443382.USD","LU0234572021.USD","LU2324357040.USD","SG9999015945.SGD","LU0471298694.HKD","LU1061106388.HKD","LU0689472784.USD","LU2063271972.USD","LU0079474960.USD","LU0289739699.SGD","LU1291159041.SGD","LU0006306889.USD","SG9999018857.SGD","LU2168564222.USD","SGXZ99366536.SGD","LU0672654240.SGD","LU2491049909.HKD","LU0122379950.USD","LU0353189680.USD","IE00BN29S564.USD","LU2750360641.GBP","LU1983299246.USD","LU2237443978.SGD","LU2211815571.USD","LU2468319806.SGD","LU0096364046.USD","LU2552382058.USD","LU1804176565.USD","SG9999018865.SGD","LU2361044865.SGD","LU0354030438.USD","IE00B775H168.HKD","LU0354030511.USD"],"gpt_icon":1},{"id":"2590851663","title":"Alt5 Sigma Corporation Announces Plans to Integrate USD1 Stablecoin Into Payment Platforms to Enhance Settlement Efficiency and Support $WLFI Treasury Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590851663","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590851663?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:08","pubTimestamp":1765458496,"startTime":"0","endTime":"0","summary":"Alt5 Sigma Corporation Announces Plans to Integrate USD1 Stablecoin Into Payment Platforms to Enhance Settlement Efficiency and Support $WLFI Treasury Strategy. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alt5 Sigma Corporation published the original content used to generate this news brief via Business Wire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL2wtvF1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALTS","BK4112"],"gpt_icon":0},{"id":"2590516579","title":"BRIEF-60 Degrees Pharmaceuticals Announces Expansion Of Arakoda Sales And Marketing In 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516579","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516579?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:06","pubTimestamp":1765458369,"startTime":"0","endTime":"0","summary":"BRIEF-60 Degrees Pharmaceuticals Announces Expansion Of Arakoda Sales And Marketing In 2026Dec 11 (Reuters) - 60 Degrees Pharmaceuticals Inc SXTP.O:60 DEGREES PHARMACEUTICALS ANNOUNCES EXPANSION OF AR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTPW","SXTP","BK4007"],"gpt_icon":0},{"id":"2590851655","title":"Cadrenal Therapeutics Acquires VLX-1005 from Veralox Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2590851655","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590851655?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:05","pubTimestamp":1765458313,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics has acquired VLX-1005, a first-in-class Phase 2 12-LOX inhibitor, along with related assets from Veralox Therapeutics. The addition of VLX-1005 bolsters Cadrenal's pipeline with a novel therapeutic candidate for the treatment of heparin-induced thrombocytopenia , a serious condition lacking therapies that target its immune-driven biology. VLX-1005 is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing and has received Orphan Drug and Fast Track designations from the FDA. Under the terms of the agreement, Veralox will receive upfront and milestone payments, as well as royalties on future global sales.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL8p84rn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","LU2095319765.USD","BK4007","BK4585","IE00B64PRP62.GBP","SG9999014005.SGD","CVKD","SG9999014021.USD","BK4588","LU0314104364.USD","SG9999014039.USD","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4112"],"gpt_icon":0},{"id":"2590851657","title":"Cadrenal Therapeutics Inc - Veralox Entitled to Royalties on Global Sales of Acquired Assets Upon Future Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2590851657","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590851657?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:05","pubTimestamp":1765458300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA1MK7FT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVKD","BK4007"],"gpt_icon":0},{"id":"2590517516","title":"Cadrenal Therapeutics Inc - Veralox Eligible for Upfront and Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2590517516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590517516?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:05","pubTimestamp":1765458300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA1MK7FT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVKD","BK4007"],"gpt_icon":0},{"id":"2590165415","title":"Cadrenal Therapeutics Acquires Vlx-1005, a First-in-Class Phase 2 12-Lox Inhibitor for Patients With Heparin-Induced Thrombocytopenia (Hit)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590165415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590165415?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:05","pubTimestamp":1765458300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA1MK7FT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVKD","BK4007"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4007","nameEN":"BK4007"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pharmacy(BK4007),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pharmacy(BK4007) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pharmacy,BK4007,Pharmacy股票,Pharmacy股票老虎,Pharmacy股票老虎国际,Pharmacy行情,Pharmacy股票行情,Pharmacy股价,Pharmacy股市,Pharmacy股票价格,Pharmacy股票交易,Pharmacy股票购买,Pharmacy股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pharmacy(BK4007),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pharmacy(BK4007) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}